TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07782827: CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)

Sponsor: Ionis Pharmaceuticals, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,351,728

Rescue Site Savings

+$8,155,912

Unlock Full NCT07782827 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07782827 Rescue Dossier →